---
title: 'Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in
  Relapsed/Refractory CLL: Phase 1b BRUIN Trial'
date: '2024-06-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38861666/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240612181555&v=2.18.0.post9+e462414
source: Blood
description: Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton
  tyrosine kinase inhibitor (BTKi). Patients with relapsed or refractory (R/R) chronic
  lymphocytic leukemia (CLL) were treated with fixed-duration pirtobrutinib plus venetoclax
  (PV) or pirtobrutinib plus venetoclax and rituximab (PVR) in this phase 1b trial
  (NCT03740529). Prior covalent BTKi therapy was allowed, but not prior venetoclax.
  Patients were assigned to receive PV (n=15) or PVR (n=10) for 25 cycles. Median
  age was ...
disable_comments: true
---
Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) were treated with fixed-duration pirtobrutinib plus venetoclax (PV) or pirtobrutinib plus venetoclax and rituximab (PVR) in this phase 1b trial (NCT03740529). Prior covalent BTKi therapy was allowed, but not prior venetoclax. Patients were assigned to receive PV (n=15) or PVR (n=10) for 25 cycles. Median age was ...